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Background: Exposure to inhaled allergens is a pathogenetic factor in allergic asthma.
However, most studies that previously looked at air cleaning devices have shown little or no
effect on patients with perennial allergic asthma.
Aims and objectives: We examined a novel treatment using temperature regulated laminar
airflow with a very low particle concentration directed to the breathing zone of teenagers and
young adults with mild to moderate allergic asthma during night sleep. We hypothesised that
the decreased allergen exposure during the night would have an effect on bronchial inflammation
and quality of life.
Method: Twenty-two patients (mean 18.8 years) were randomized to start with active or placebo
treatment for 10 weeks. All patients received both active and placebo treatment with unfiltered
air, with a 2-week wash-out period in between treatments. Maintenance treatment with inhaled
corticosteroids was unaltered during the trial period. Health related quality of life (miniAQLQ)
was the primary effectiveness measure. Exhaled nitric oxide (FeNO) and spirometry were also
investigated.
Results: Active treatment resulted in an improved miniAQLQ compared to placebo (mean score
0.54, p < 0.05, nZ 20). An effect on bronchial inflammation was also detected with significantly
lower FeNO values during the active treatment period (mean 6.95 ppb, p < 0.05, nZ 22). Both
effects were evident after 5 weeks. The change in lung function was not statistically significant.
Conclusion: Cleanair, administereddirectly to thebreathingzoneduring sleep, canhaveapositive
effect on bronchial inflammation and quality of life in patients with perennial allergic asthma.
ª 2009 Elsevier Ltd. All rights reserved.625 1930; fax: þ46 8 5177 773.
tti@karolinska.se (C. Pedroletti).
9 Elsevier Ltd. All rights reserved.
1314 C. Pedroletti et al.Introduction Table 1 Individual data for demographics, baseline scores
previous to first period, asthma treatment and skin prick
test at randomization.
Number of patients 22
No. (%) of female participants 12 (54.5)
Age (years) 18.5 (6.6)
Age range (years) 12e33
No. (%) using daily ICS
Low dosea 13 (59.1),
Medium dosea 8 (36.3)
High dosea 1 (6.6)
No. (%) using daily LABA 19 (86)
No. (%) using daily LTRA 7 (31.8)
Quality of life score, miniAQLQ (max. of 7.0) 5.18 (1.1)
FeNO (ppb) 32.8 (24.1)
FEV1 predicted 77.9 (16.5)
No. (%) pet sensitised 22 (100)
No. (%) of sensitisations pet  mite  birch
nZ 1 5 (22.7)
nZ 2 12 (54.5)
nZ 3 5 (22.7)
a According to GINA. ICS, inhaled corticosteroids; LABA, long-
acting beta-agonists; LTRA, leukotriene receptor antagonist.Asthma is an inflammatory disease. In allergic asthma the
inflammation is mainly driven by the exposure to inhalant
allergens to which the patient is sensitised.
Minimising the exposure to inhalant allergens, such as
animal dander and house dust mites, is a first step in
reducing the severity of asthma.1,2 Experiences from high
altitude studies3,4 suggest that long term avoidance of
house dust mite allergens leads to a decrease in airway
inflammation with consequent symptom improvement.
Most studies that previously used air cleaning devices and
other ventilation measures to remove allergen have shown
little or no effect on patients with perennial allergic asthma,5
suggesting that the allergen reduction had simply not been
significant enough to affect airway inflammation. The
perennialallergensarewidespreadandhavebeenshowntobe
prevalent even in the homes of people who don’t own pets.6
In this study, we investigated a novel treatment, Airsonett
Airshower (AA), that uses a laminar airflow of purified air
directed to the breathing zone of a patient during night sleep.
We hypothesised that AA treatment on top of inhaled corti-
costeroids (ICS) medication would lead to a decreased airway
inflammation with consequent symptom improvement in
patients with allergic asthma.Materials and methods
Subjects
Perennial allergic asthmatic adolescents and young adults,
12e33 years of age, taking a daily maintenance dose of at
least ICS 400 mg/day of budesonide or 200 mg/day of fluti-
casoneand short actingbeta 2-agonist treatment on less than
4 days per week, were included into the study. The subjects
were recruited at the departments of child allergy Karolinska
University Hospital, Stockholm, and at the University
Hospital in Linko¨ping. All patients had been examined,
diagnosed, and followed by a specialist in allergology with
the diagnosis of allergic asthma for many years. The asthma
diagnosis had been confirmedby lung function testing and/or
bronchial provocation test (metacholine and/or cold dry air).
All subjects were sensitive to pet allergen (cat and/or dog),
as demonstrated by positive skin prick test (3 mm) for the
allergens. The subjects were also tested for mould spores,
house dust mites and birch pollen with positive reactions in
most patients (see Table 1). Patients were excluded if they
were current smokers, were included in another allergen
avoidance program, were in drug trials and if they were on
allergen specific immunotherapy.
The study was approved by the regional ethic committee
at Karolinska Institutet, Stockholm, Sweden (reference
number 2005-1048-31/1) and both the subjects and, if
under age, their parents gave informed consent prior to
entering the trial.
Study device
The AA treatment is designed to reduce the allergen load in
the patients breathing zone by vertically displacing theallergens, originating from the bed and the ambient room
environment, with a temperature controlled laminar
airflow (TLA) during night sleep (see Fig. 1). The airflow is
filtered through a high efficiency particulate air filter
(HEPA), slightly cooled and ‘‘showered’’ over the subject.
Due to the higher density, the cooled air descends slowly,
and displaces the allergens from the breathing zone. TLA
has been evaluated in industrial environments for local
control of air pollutants.7
The function of the devices in this trial was validated at
rest when placed in the patient’s bed rooms according to
standard ISO 14644-2 Clean rooms and associated
controlled environments. In the validation of the clean
zone, the active devices had maximum permitted level of
5000 particles/ft3 of particles 0.5 mm of the particle count
of ambient room air. The reduction in exposure integrated
over night was not measured in this trial. Earlier technical
studies8 have indicated that the exposure is less than
5000 particles/ft3, of particles 0.5 mm, but further studies
are needed to evaluate this.
In a placebo device the filtration function was disabled.
None of the patients reported that they could sense or hear
the difference between an active and a placebo device.Study design
The study was designed as a two-centre, double-blind,
placebo-controlled, crossover trial. The patients were
randomized into one of two arms starting with either active
or placebo treatment followed by a washout period of
2 weeks with no use of the device and ending with a second
period of either active or placebo treatment (Fig. 2). Each
treatment period was 10 weeks long and all subjects
maintained their medication (see Table 1) from
Figure 1 Function of AA treatment (left) compared to traditional air cleaning (right). AA treatment creates an allergen free zone
directed to the airways whilst traditional air cleaning aims to dilute the allergen levels in the whole room.
Clinical effects of purified air administered to the breathing zone in allergic asthma 1315randomization throughout the study. Inhaled, short-acting
beta 2-agonists were allowed as rescue treatment.
The subjects were monitored at regular visits with
spirometry and exhaled nitric oxide (FeNO) measurements
at weeks: 0 (randomization), 5, 10 (end of first active/
placebo period), 12 (start of second placebo/active
period), 17, 22 (end of the trial).
Outcome variables
The primary effectiveness measure for evaluation was the
change in quality of life between active versus placebo
treatment, assessed by the mini-Asthma Quality of Life
Questionnaire (miniAQLQ). The miniAQLQ is a well-known
and validated quality of life assessment instrument for use
in asthma9e11 capable of showing beneficial treatment
effects, from the patient’s perspective, not captured by
objective monitoring. We defined the change in quality of
life as the difference in the miniAQLQ summary score from
start to end (10 weeks) of each study period. A miniAQLQ
scores from 0 to 7, where 7 is no symptoms. A change of 0.5
is considered clinically significant.
Exhaled nitric oxide (FeNO) was measured at each visit
followed by spirometry. Single-breath, on-line measure-
ment of FeNO was performed in accordance with the
recommendations of the American Thoracic society1222 Patients
mean 18.8 yr 
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Figure 2 Randomization of subjects into two arms of treatme
F, FENO; S, spirometry; P, physical examination; U, urine sample.(ATS). FeNO was measured with the Aerocrine NIOX
(Aerocrine AB, Stockholm, Sweden). Spirometry was per-
formed in accordance with ATS guidelines13 to calculate
forced expiratory volume in 1 s (FEV1), and peak expiratory
flow rate (PEF). Each patient maintained a daily diary
recording of lost school/workdays, quality of sleep and use
of medication.
Statistical analysis
The study hypothesis was tested by examining the difference
in change of miniAQLQ, FeNO and spirometry during active
versus placebo treatment periods. All subjects who
completed measurements at both baseline and endpoint of
each treatment period were analyzed. Results were summa-
rized by treatment periods as mean scores  confidence
interval. Changes frombaselinewithin each treatment period
(active or placebo) were analyzed using paired t-tests.
An analysis of variance (ANOVA) model was used to compare
the changes (measured as least square mean  confidence
interval) between the two treatment periods. The country
and baseline scores were variates in this model. We calcu-
lated that a sample size of 20 would have a 62% power to
detect a 30% improvement of miniAQLQ for active treatment
vs placebo, with the error set at 0.05 and SD based on
a previous pilot study.14o 
2 w 
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nt: activeeplacebo or placeboeactive. Clinical assessments:
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Demographics
In total, 28 patients were enrolled and had AA devices
installed in their home bed rooms. Of these, 22 completed
measurements at baseline and endpoint of both treatment
periods. Two patients withdrew due to pregnancies, one
patient due to change of location and failure to complete
the protocol, and another two patients withdrew for non
medical reasons. One patient was excluded from study
analysis due to an incorrectly adjusted study device during
the first treatment period. Two of the 22 patients failed to
complete the miniAQLQ and therefore could not be
included in the miniAQLQ analysis.
The missing data analysis showed only random features
of missing data.
Eight episodes of asthma exacerbations were reported
with increased reliever medication (beta 2 agonists >
4 days per week). One patient also used a temporary
increase in steroid medication. Four of the episodes were
during active period, three were judged as being caused by
viral infections and one was of no reported cause. Four
episodes occurred during placebo treatment, all four were
probably due to other viral infections. Three of the eight
exacerbations were reported from one subject, two from
another, and the remaining three from three different
subjects.
Individual data for demographics, baseline scores,
asthma treatment and positive skin prick test at
randomization are presented in Table 1. The 22 subjects
recorded a mean FeNO of 32.8 ppb (95% CI, 22.2e43.5,
nZ 22) and a mean miniAQLQ score of 5.18 (95% CI,
4.67e5.70, nZ 20) at randomization. Their mean FEV1
was 92% of predicted.
Change in quality of life and fraction of exhaled
nitric oxide
The mean improvement in the overall miniAQLQ score in
the active treatment group was greater than in the placebo
group (mean difference 0.54; SEM  0.28, p < 0.05)
(Table 2). The effect seemed to occur already after 2 weeks
of treatment and was evident after 5 weeks. The changes in
the miniAQLQ score and FeNO values in the two treatment
periods are shown in Fig. 3.
FeNO was significantly reduced by 6.4 ppb (SEM  2.5,
p < 0.05) after 10 weeks of active treatment as compared
with placebo (Fig. 3). The reduction was already discernibleTable 2 The difference in change, miniAQLQ score and FeNO v
Variable Active treatment
(geometric mean (95% CI))
Placebo
(geome
Start End Start
FeNO (ppb) 29.2
(18.9e39.5)
22.2
(14.8e29.7)
29,0
(18.2e3
miniAQLQ 5.36
(4.82e5.90)
5.92
(5.56e6.28)
5,69
(5.23e6after 5 weeks of treatment (first measurement after base-
line). The confidence interval of FeNO at the end of the
placebo period was greater than at the end of the active
period, implying a better control of asthma with an active
treatment (Table 2). Patients with more symptoms i.e.
a low miniAQLQ score (<5) and high FeNO (>16 ppb)
showed greater treatment effect but the sample size was
considered too small for subgroup analysis.
Four ‘‘drop-out’’ patients filled the miniAQLQ form
before and after at least one study period. Three of them
had been given active treatment and demonstrated an
increase in two cases (þ0.47 and þ0.47) and a minor
decrease in one case (0.27). The fourth patient received
placebo treatment and showed a minor increase in the
miniAQLQ score (þ0.27).
FeNO values were obtained at the start and at the end of
at least one study period in three excluded patients. All
three patients got active treatment but showed small
effects on FeNO (þ3.6 ppb and 3.4 ppb and 0.9). If these
patient data are included in a statistical evaluation
a ‘‘parallel group design’’ with lower sensitivity has to be
used. The result of such a calculation shows a mean
increase in miniAQLQ of 0.73 in the active group and 0.02
in the placebo (pZ 0.056). The effect on FeNO was smaller
(4.43 ppb active vs 0.25 ppb placebo) and was not
significant (pZ 0.25).
Spirometry
When the changes of FEV1 and PEF values were considered,
small, not significant increases during active periods were
observed (mean percentage difference in FEV1Z 1.14%,
mean percentage difference in PEFZ 3.44%).
Discussion
There are several phenotypes of asthma and various factors
play a role in the pathogenesis and symptom development
of the disease. In order to show an effect of allergen
avoidance we selected young patients in whom we consid-
ered allergen exposure to be of importance for their
asthma.
All subjects were sensitive to pet allergen (cat and/or
dog), as demonstrated by positive skin prick test (>3 mm).
Pet allergen is also the dominating allergen to which young
Scandinavian asthmatics are sensitised. High levels of cat
allergen are found in homes of non cat owners and it has
been shown that allergen is spread via clothing from homes
with cats to classrooms, and further to homes without cats.alues, between active and placebo treatment.
treatment
tric mean (95% CI))
Difference in change:
mean  SEM, p-value,
n activeeplaceboEnd
9.8)
28,5
(16.4e40.6)
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.14)
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Figure 3 Cross-over variations of miniAQLQ and FENO for
each time point of the study. Quality of life e miniAQLQ
(nZ 20) is presented in % of baseline (week 0). Bronchial
inflammation is presented in ppb, forced exhaled nitric oxide
(nZ 22). FENO baseline mean values (week 0) were 29.2 ppb
for active treatment and 29.0 ppb for placebo treatment.
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non-cat owners’ homes correlate with children’s exposure
to cat allergen at school.6 Cat allergens are small and easily
airborne from reservoirs such as beds or other furniture.
Movements in bed make the allergens respirable and this
exposure may maintain a bronchial inflammation. The fact
that avoidance of exposure to indoor allergens could be an
important element in the treatment of allergic asthma is
shown by studies in mite-allergic children in high altitude
environments where a major reduction in mite allergen
levels resulted in a significant reduction in bronchial
inflammation.3
One limitation of the study is that we did not measure
the actual exposure to possible allergens in the breathing
zone. Therefore, we cannot asses the impact of a certain
amount of allergen reduction on our results. However, the
results should not have been skewed by differences in
patients’ bedroom environments since this investigation
was a cross-over study.
Many studies of allergy and asthma have been made with
various air cleaning devices in the home setting, showing
little or no effect on the disease. In two studies, using clean
air delivered directly to the breathing zone showed more
promising results.15,16 These devices, however, have not
been used in clinical settings due comfort problems such as
draft and high sound levels.
Due to air cooling a low flow, more silent fans can be
used in the airshower technique. The AA creates a zone of
purified air which displaces contaminants from the airspace
around the bed environment. The cleaning effect of
airborne particles in the breathing zone is accomplished
within minutes and the reduction in allergen and particle
concentration is significantly reduced8 (see Fig. 1). The
efficient allergen reduction in the breathing zone is what
makes AA treatment different from earlier air cleaning
techniques and may explain the positive clinical outcome in
this study.
The effect of AA treatment may be due to more
dimensions than a decrease in allergen exposure. Apartfrom the avoidance of allergens a decreased exposure to
airborne particles could be of importance. They may act as
irritants or have a proinflammatory effect.
In a recent study of the effects of airshower filtering of
the air in the homes of elderly subjects living near major
roads in Copenhagen, it was shown that indoor particles
affected vascular function.17 The effect might be caused by
inflammatory mechanisms.18
The Airshower technique has been shown to reduce
exposure significantly in workplaces,7 is widely used in
clean room environments of the electronics industry19 and
is also increasingly used in operating theatres.
Subjective measurements of AQLQ showed a clinically
meaningful and statistically significant improvement with
active AA treatment compared to placebo treatment. Some
of the patients also spontaneously reported less nasal
symptoms during active treatment. The results from the
present study show that the allergen reduction with AA
treatment is significant enough to affect the airway inflam-
mation even if the time with clean air is limited to the night.
The fact that exhaled NO levels were lower during AA
treatment supports the view that allergen exposure and
induced airway inflammation was of importance in our
patients.
The decrease in FeNO levels in our patients were
significant in spite of the fact that they were on regular
maintenance treatment with 400 mg/day of ICS (budeso-
nide or equivalent dose). ICS is well known for its evident
lowering effect on exhaled NO,20 thus the medication could
mask an effect on FeNO by the AA treatment and a more
evident decrease might have been observed if the patients
had lower ICS dosages. The findings in this study fit well
with the results of comparative studies of young asthmatics
in which mite allergen avoidance by living in an alpine
resort resulted in reduced FeNO values.3,4
The AA treatment was used as an add-on treatment to
ICS and for this reason the daily ICS dose was not altered
with randomization. The selection criteria for the study
were subjects with partly controlled (the Global Initiative
for Asthma, GINA, 2006) moderately severe asthma (GINA,
2002), and for this subject group a recommended step is for
example to add on LTRA to the ICS treatment. Our
hypothesis was that AA treatment could be considered as
an alternative add-on therapy for improved asthma control.
Add-on AA treatment is hardly cost motivated in subjects
with mild, easily controlled asthma.
The miniAQLQ and FeNO were chosen as primary
outcome variables to record subjective and objective
measures of asthma. The miniAQLQ was chosen to measure
symptom improvement effects on daily life and FeNO was
chosen to acquire objective measures of asthma bronchial
inflammation. There is good evidence that exhaled nitric
oxide reflects eosinophilic airway inflammation in asthma21
and we thought that the nightly reduction of allergen
exposure, that AA treatment provides, could be of special
importance since both symptoms and eosinophilia tend to
be higher at night. Our data is supported by previous find-
ings from Grootendorst and colleagues who also reported
an improvement in miniAQLQ after 10 weeks of sojourns in
high altitude.22
No significant change in FEV1 was recorded in the
present study. This may partly be explained by the
1318 C. Pedroletti et al.relatively good spirometry values the recruited patients
had at the beginning. The lack of FEV1 response is in
agreement with a high altitude study3 where all subjects
were treated with ICS from inclusion. In this study the mite
allergen avoidance led to a significant decrease of the
residual volume, and to a parallel significant reduction of
inflammation, measured by FeNO, implicating improve-
ments in the peripheral airways not reached by ICS
medication.
In our study the positive response for QoL was already
apparent after the first measurements at 2 weeks and FeNO
after the first measurements at 5 weeks, and the improve-
ments were maintained throughout the study. It could have
been of value if FeNO had been measured more frequently in
the beginning of each period as this marker is known to react
rapidly to anti inflammatory treatment.23 Furthermore, the
fact that the FeNO values were similar, the start of each
treatment period (see Table 2) indicates a rapid reversal of
this parameter since the washout period was only 2 weeks.
The material was not large enough to show a significant
correlation between MiniAQLQ and FeNO but did indicate
a tendency suggesting that patients with lower QoL score at
baseline had the greatest improvement in both QoL and
FeNO values.
The patient material of this study was of a selected
asthma phenotype, i.e. young adults with typical allergic
asthma. In an older group of patients, clinical effects of AA
treatment might possibly take a longer time because more
chronic asthma is associated with secondary changes.
Finally, there were six drop-outs in our study due to
different reasons specified in the Results section. In three
of these cases FeNO values could be obtained during at
least one study period and in three cases the miniAQLQ
form was filled in.
Since these subjects did not carry out both study periods,
they could not be part of a cross-over analysis. However,
including these patients and recalculating the data as
a parallel group study also showed a positive effect of the
intervention, but did not reach statistical significance.Conclusion
In conclusion, improvements in FeNO levels and QoL were
significantly greater after AA add-on treatment compared
with placebo add-on treatment in this group of adolescents
and young adults taking regular ICS 400 mg/day of bude-
sonide or 200 mg/day of fluticasone. Patients with low QoL
score at baseline showed greater improvement in both QoL
and FeNO values.
The clinical effect of this novel non pharmaceutical
intervention shows promising results as an additive measure
for the treatment of perennial allergic asthma. However,
the clinical relevance of these findings needs to be verified
in larger controlled trials to be able to make general
treatment recommendations.Conflict of interest statement
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